Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-12-18 | New | $3,950,000 | $3,950,000 | Equity Only | 06b | SEC link |
| 2023-12-29 | New | $3,000,000 | $3,000,000 | Debt Only | 06b | SEC link |
| 2021-02-25 | New | $4,969,000 | $4,969,000 | Debt Only | 06c | SEC link |
| 2018-03-07 | Amended | Yet to Sell | $0 | Equity Only | 06c | SEC link |
| 2017-12-07 | New | Yet to Sell | $0 | Equity Only | 06c | SEC link |
| 2017-11-22 | New | Yet to Sell | $0 | Equity Only | 06c | SEC link |
| Name | Role |
|---|---|
| Kevin Barrett | Executive |
| Kevin Bassett | Director, Executive |
| Buzz Benson | Director |
| Mark Ereth | Executive |
| Daniel Halpern | Director, Executive |
| Sandi Klemann | Executive |
| James Knapp | Director |
| Andy La Frence | Director |
| Jim Segermark | Executive |
| Ivan Shaw | Director |
| Bill Taylor | Executive |
| Greg Van Guilder | Director |
| Kay Warnott | Executive |
| Robert Wilson | Director |